Get the Stockscreener App
37.38
2.92%
1.06
Septerna Inc stock is traded at $37.38, with a volume of 109.79K.
It is up +2.92% in the last 24 hours and down -3.81% over the past month.
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.
See More
Previous Close:
$36.32
Open:
$36.78
24h Volume:
109.79K
Relative Volume:
0.22
Market Cap:
$1.74B
Revenue:
$45.95M
Net Income/Loss:
$-48.88M
P/E Ratio:
-33.59
EPS:
-1.1129
Net Cash Flow:
$109.67M
1W Performance:
+1.30%
1M Performance:
-3.81%
6M Performance:
+44.16%
1Y Performance:
+60.22%
1-Day Range:
$36.22
$38.36
1-Week Range:
$34.36
$38.73
52-Week Range:
$17.55
$51.10
Septerna Inc Stock (SEPN) Company Profile
Name
Septerna Inc
Sector
Industry
Phone
650-338-3533
Address
250 EAST GRAND AVENUE, SUITE 65, SOUTH SAN FRANCISCO
Compare SEPN vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SEPN
Septerna Inc
|
37.38 | 1.74B | 45.95M | -48.88M | 109.67M | -1.1129 |
VRTX
Vertex Pharmaceuticals Inc
|
509.74 | 129.20B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
238.40 | 95.18B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
801.26 | 82.49B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
849.01 | 53.39B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
371.37 | 42.01B | 5.76B | 514.49M | 1.10B | 4.4813 |
Septerna Inc Stock (SEPN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-11-26 | Initiated | Guggenheim | Buy |
| May-01-26 | Initiated | Stifel | Buy |
| Dec-19-25 | Initiated | Raymond James | Strong Buy |
| Dec-15-25 | Initiated | Truist | Buy |
| Nov-14-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jun-23-25 | Initiated | H.C. Wainwright | Buy |
| Feb-18-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-19-24 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-19-24 | Initiated | JP Morgan | Overweight |
| Nov-19-24 | Initiated | TD Cowen | Buy |
| Nov-19-24 | Initiated | Wells Fargo | Overweight |
View All
Septerna Inc Stock (SEPN) Latest News
Septerna Officer Samira Shaikhly Files Form 144 to Sell 12,592 Common Shares - Kalkine Media
Officer Daniel Long proposes selling 10,001 Septerna (SEPN) common shares. - Stock Titan
An officer proposes selling 12,592 Septerna (SEPN) shares acquired by exercising stock options. - Stock Titan
Septerna, Inc.Common Stock (NQ: SEPN - The Chronicle-Journal
Septerna's CMO Rajiv Patni Granted 275,000 Stock Options with 10-Year Expiry - Kalkine Media
Septerna (SEPN) awards CMO 275,000 options at $37.37 - Stock Titan
Septerna, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - manilatimes.net
Septerna Announces Inducement Grant Under Nasdaq Listing Rule - TradingView
A new medical chief gets an option to buy up to 275,000 Septerna shares at $37.37 - Stock Titan
Septerna, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - lincolnjournal.com
Septerna, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Carroll County Mirror-Democrat
Septerna at Cantor Fitzgerald conference: pipeline broadens, cash holds By Investing.com - Investing.com Canada
Septerna at Cantor Fitzgerald conference: pipeline broadens, cash holds - Investing.com India
Septerna at Wells Fargo conference: platform bets and pipeline catalysts By Investing.com - Investing.com Canada
Septerna SVP Daniel Long sells $126,077 in company stock By Investing.com - Investing.com South Africa
Septerna SVP Daniel Long sells $126,077 in company stock By Investing.com - Investing.com Nigeria
Septerna SVP Daniel Long sells $126,077 in company stock By Investing.com - Investing.com Canada
Septerna SVP Daniel Long sells $126,077 in company stock - Investing.com
Septerna SVP Daniel Long sells $126,077 in company stock By Investing.com - Investing.com India
New Septerna (SEPN) chief medical officer reports zero share holdings - Stock Titan
Septerna SVP Drug Discovery Daniel D. Long disposes of common shares worth $126,081.52 - Bitget
Septerna to Participate in Upcoming Investor Conferences - manilatimes.net
Septerna to Participate in Upcoming Investor Conferences - marketscreener.com
Septerna (SEPN) Declines 1.95% to $38.15, Approaching Key Support at $36.24Parabolic SAR - vinanet.vn
Septerna (SEPN) Declines 1.95% to $38.15, Approaching Key Support at $36.24Momentum Factor - dars.gov.et
Septerna Inc Q2 Income From Operations USD -1 - moomoo.com
Septerna (SEPN) Is Down 7.1% After Broad Russell Index Additions Has The Bull Case Changed? - sahmcapital.com
Septerna stock soars 315% on Novo Nordisk deal and key drug milestones - Pluang
Septerna appoints Rajiv Patni as chief medical officer By Investing.com - Investing.com Canada
Septerna Appoints Rajiv Patni as Chief Medical Officer - TipRanks
Septerna appoints Rajiv Patni as chief medical officer By Investing.com - Investing.com India
Septerna appoints Rajiv Patni as chief medical officer By Investing.com - Investing.com Nigeria
Septerna appoints Rajiv Patni as chief medical officer By Investing.com - Investing.com UK
Septerna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical Officer - The Manila Times
Septerna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical Officer - Barchart.com
Septerna (SEPN) Results at a Glance: The Bottom-Line Figure Outpaces Its Comparison in the Latest Reading; Market Response: The Share Price Adds 1.30% in the Latest SessionEarnings Beat Streak - siam.in
Septerna (SEPN) Results at a Glance: The Bottom-Line Figure Outpaces Its Comparison in the Latest Reading; Market Response: The Share Price Adds 1.30% in the Latest SessionMargin Guidance - dars.gov.et
Septerna (SEPN) Results at a Glance: The Bottom-Line Figure Outpaces Its Comparison in the Latest Reading; Market Response: The Share Price Adds 1.30% in the Latest SessionGuidance Revision Trend - vinanet.vn
Septerna (SEPN) Shares: Finishes 2.10% Higher at $40.84 for the Current Session; Immediate View: Support at $38.80 and Resistance at $42.88 Frame the Range in Latest TradingStandard Deviation - vinanet.vn
Septerna (SEPN) Shares: Finishes 2.10% Higher at $40.84 for the Current Session; Immediate View: Support at $38.80 and Resistance at $42.88 Frame the Range in Latest TradingSector ETF Flow - siam.in
Driehaus Capital Management Expands Septerna Inc (SEPN) Stake in Second Quarter - GuruFocus
Septerna (NASDAQ:SEPN) Stock Price Down 8%Time to Sell? - MarketBeat
Analysts Offer Insights on NA Companies: Cerebras Systems, Inc. Class A (CBRS), Septerna, Inc. (SEPN) and TWFG, Inc. Class A (TWFG) - theglobeandmail.com
SEPN Maintained by JP Morgan -- Price Target Raised to $48 - GuruFocus
Septerna (NASDAQ:SEPN) Price Target Raised to $48.00 - MarketBeat
J.P. Morgan Maintains Septerna(SEPN.US) With Buy Rating, Raises Target Price to $48 - Moomoo
SEPTERNA, INC. : JP MORGAN RAISES TARGET PRICE TO $48 FROM $38 - Bitget
4,211,659 Shares in Septerna, Inc. $SEPN Acquired by Trv Gp Vi LLC - MarketBeat
Trv Gp V LLC Takes Position in Septerna, Inc. $SEPN - MarketBeat
Septerna, Inc. (SEPN) Receives a Rating Update from a Top Analyst - The Globe and Mail
Septerna Inc Stock (SEPN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Septerna Inc Stock (SEPN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| SAMIRA SHAIKHLY | Officer |
Oct 01 '26 |
Proposed Sale |
39.13 |
12,592 |
492,725 |
0 |
| Long Daniel D. | SVP, Drug Discovery |
Sep 01 '26 |
Option Exercise |
2.76 |
3,333 |
9,199 |
99,745 |
| Long Daniel D. | SVP, Drug Discovery |
Sep 01 '26 |
Sale |
37.83 |
3,333 |
126,078 |
96,412 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Aug 12 '26 |
Sale |
42.50 |
1,493,000 |
63,452,500 |
725,443 |
| Third Rock Ventures V, L.P. | 10% Owner |
Aug 12 '26 |
Proposed Sale |
51.00 |
147,200 |
7,507,200 |
0 |
| RA Capital Nexus Fund III, L.P | Affiliate |
Aug 12 '26 |
Proposed Sale |
48.19 |
746,500 |
35,973,835 |
0 |
| RA Capital Healthcare Fund LP | affiliate |
Aug 12 '26 |
Proposed Sale |
48.19 |
746,500 |
35,973,835 |
0 |
| Bhatt Elizabeth | President and COO |
Aug 11 '26 |
Option Exercise |
5.79 |
25,000 |
144,658 |
199,209 |
| Bhatt Elizabeth | President and COO |
Aug 11 '26 |
Sale |
44.00 |
25,000 |
1,100,000 |
174,209 |
| ELIZABETH P. BHATT | Officer |
Aug 11 '26 |
Proposed Sale |
38.85 |
29,000 |
1,126,650 |
0 |
0.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):